Sensex
80,364.49 profit arw 554.84 (0.70%)
Nifty
24,625.05 profit arw 198.20 (0.81%)
Nasdaq
18,355.20 profit arw -497.09 (-2.64%)
logo img

GET IN TOUCH

GET IN TOUCH

Refresh Captcha
Equity

As on : 22-Aug-2025
Hot Pursuit
22-Aug-2025     12:40

Divis Lab gains as broker reiterates buy call

The brokerage downplayed concerns over Eli Lilly's oral GLP-1 candidate Orforglipron and generic risks to Novartis' heart drug Entresto, which contributes about 20% of Divi's consolidated revenue. It expects Divi's to remain a key API supplier, supported by a healthy order pipeline and rising demand in peptides, making the recent stock weakness a buying opportunity.

Over the past month, the stock has fallen 7.08% compared with a 0.84% decline in the Sensex.

Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. The company's consolidated net profit rose 26.74% to Rs 545 crore while net sales rose 13.79% to Rs 2410 crore in Q1 June 2025 over Q1 June 2024.

Powered by Capital Market - Live News

INDIAN INDICES

Sensex

80,364.49 554.84 (0.70%)

Nifty

24,625.05 198.20 (0.81%)

GLOBAL INDICES

USD

NA

NASDAQ
HANG SENG

25,617.43 539.80(2.15%)